NCT03285711 - Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 6, 2017

Primary Completion Date

May 3, 2019

Study Completion Date

February 3, 2020

Conditions

Lupus Membranous Nephropathy

Interventions

DRUG

Filgotinib

200 mg tablet administered orally once daily

DRUG

Lanraplenib

30 mg tablet administered orally once daily

DRUG

Filgotinib placebo

Tablet administered orally once daily

DRUG

Lanraplenib placebo

Tablet administered orally once daily

Trial Locations (7)

Georgia Nephrology Research Institute, Lawrenceville

Emory University School of Medicine, Atlanta

University of Alabama at Birmingham (UAB), Birmingham

University of Michigan, Ann Arbor

Stanford University, Palo Alto

University of Florida, Gainesville

University of North Carolina at Chapel Hill / UNC School of Medicine, Chapel Hill